PRESIDENT AND CHIEF EXECUTIVE OFFICER
Leah received a Ph.D. in medicinal chemistry from the University of Michigan in 2014, and a B.S. in biochemistry from the University of Dayton in 2009. She developed ViewPoint's flagship technology as a graduate student in Jason's lab and cofounded the company. While at the University of Michigan, she participated in the Pharmacological Sciences Training Program, was a fellow of the American Foundation for Pharmaceutical Education, and was named an Alzheimer's Drug Discovery Foundation Young Investigator. Leah has expertise in biophysical methods, protein biochemistry, high-throughput screening, and medicinal chemistry.
CHIEF MEDICAL OFFICER
Bob joined Viewpoint Therapeutics as Chief Medical Officer in May 2018. He is a board-certified ophthalmologist who comes to Viewpoint from Genentech, Novartis, GSK, Carl Zeiss Meditec, and most recently Apellis Pharmaceuticals. He has been involved in Phase 1-3 development of numerous drugs, including Lucentis, Simbrinza, Pazeo, and most recently pegcetacoplan (APL-2). Bob completed his residency in ophthalmology at the University of California, San Francisco (UCSF), post-doctoral training in molecular biology of lens crystallins at the NIH, and retina fellowship training at Moorfields Eye Hospital in London. He received his undergraduate and MD degrees from Brown University and an MBA from UC Berkeley. He is currently an Associate Clinical Professor of Ophthalmology at UCSF, where he continues to see patients.
VP OF CHEMISTRY
Paul joined ViewPoint in June 2017 as Vice President of Chemistry. He has over 25 years of medicinal chemistry experience in roles of increasing leadership and has successfully overseen the chemistry and early CMC activities for multiple research programs. Prior to joining ViewPoint, Paul was at Theravance Biopharma (formerly Theravance Inc.) for 20 years, most recently as Senior Director of Chemistry where he was involved in the identification of over 7 differentiated clinical candidates across multiple indications, target classes, and routes of administration including Vibativ® (televancin), Velusetrag (TD-5108), and Cefilavancin (TD-1792).
Prior to Theravance, Paul was a chemist at Arris Pharmaceuticals and Syntex Research. Paul holds a B.S. in Chemistry from the University of California, Santa Barbara.
ViewPoint is further supported by a team of consultants and contractors with deep expertise in medicinal chemistry, formulations, preclinical and clinical development, chemistry manufacturing, and regulatory affairs.